Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience.
Sign Up to like & getrecommendations! Published in 2021 at "Hematological oncology"
DOI: 10.1002/hon.2939
Abstract: The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post-ASCT maintenance treatment with… read more here.
Keywords: hodgkin lymphoma; cell transplantation; stem cell; post ... See more keywords
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/bmt.2017.196
Abstract: Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies… read more here.
Keywords: lymphoma; transplant maintenance; maintenance; post asct ... See more keywords
Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003857
Abstract: The immediate postautologous stem cell transplant (ASCT) period in multiple myeloma represents a unique opportunity for long-term disease control because many patients have eradicated most of their disease but also a challenge because it is… read more here.
Keywords: multiple myeloma; itme; cell; post asct ... See more keywords
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022007706
Abstract: Improved biomarkers are needed to guide the optimal use of autologous stem cell transplantation (ASCT) for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified using immunoglobulin… read more here.
Keywords: cell; stem cell; relapse; mrd ... See more keywords